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Abstract Primate growth hormones (GH) activate both primate
and non-primate somatotrophic receptors (GH receptors), but
non-primate GHs do not activate primate GH receptors.
Previous studies argued the interaction of Asp171 of human GH
and Arg43 of the receptor produced an attractive ionic
interaction. In non-primate GHs, His170 replaces the homologous
Asp171, producing a repulsive interaction with Arg43 of the
primate receptor which was believed to reduce the attraction of
non-primate GH for the human GH receptor, thus providing
species specificity. In this report, H170D bovine GH had activity
and affinity for human GH receptors approaching those of
human GH. In contrast, replacing Asp171 of human GH with His
did not significantly reduce somatotrophic activity, indicating
that species specificity is not wholly explained by this residue’s
interaction with Arg43 of the receptor. Deletion of either Phe44 (a
residue present only in primate GHs) or residues 32^46 (20-kDa
form of human GH) each only marginally reduced somatotrophic
activities. But the combination of the D171H mutation with
either vPhe44 or v32^46 in human GH reduced binding and
activity in a greater than additive fashion, indicated a functional
interaction between these distant structural features. In bovine
GH addition of phenylalanine at position 44 increased the
somatotrophic activity and receptor affinity in cells containing
the human GH receptor. The combination of the H170D
mutation and the addition of phenylalanine at position 44
created a bovine GH with activity indistinguishable from wild-
type human GH. Based on evidence from both bovine and human
GHs, the cooperative interaction of these two distant motifs
determined the species specificity and indicated that structural
plasticity was a critical feature necessary for the species
specificity of somatotrophic activity.
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1. Introduction
Primate growth hormones (GH) bind and activate both
primate and non-primate GH receptors by dimerizing two
receptors which bind at sites 1 and 2 on the ligand surface
[1^5] ; non-primate GHs bind and activate non-primate GH
receptors but have very limited activity for primate GH re-
ceptors [6,7]. The ligand selectivity of the primate GH recep-
tors was ¢rst recognized in 1956 [8] but has only recently been
explored at the structural level using mutagenic studies with
recombinant GHs and receptors. A comparative study of the
human and bovine GH receptors by Laird et al. [9] ¢rst iden-
ti¢ed by mutagenesis Arg43 of the human GH receptor as a
determinant of species speci¢city. Subsequent three-dimen-
sional structures of trimeric complexes of human GH with
the extracellular domain of the human GH receptor (GH
binding protein, GHbp) (Protein Data Bank #3HHR) [10]
showed Arg43 of the receptor formed two hydrogen bonds
with Asp171 and Thr175 of human GH. Using this structural
information and sequence alignment studies from several spe-
cies Souza et al. [11] suggested that the ligand speci¢city dis-
played by primate GH receptors was among the 14 amino
acids participating in the molecular interactions within the
site 1 interface. Arg43 of the human GH receptor was replaced
by leucine in all non-primate receptors while Asp171 of human
GH was substituted by histidine in all non-primate GHs. All
other residues participating in ligand^receptor interactions
within site 1 were highly conserved. The increased size and
charge of the histidine replacement at position 1701 of non-
primate GHs was suggested to be incompatible with Arg43 of
primate GH receptors but compatible with Leu43 of non-pri-
mate GH receptors. In contrast to Asp171, Thr175 of the GHs
was conserved in all species examined. The role played by
Asp171 and Arg43 has been investigated in several studies using
site-directed mutagenesis [9,11^13] and most studies conclude
that this interaction is critical for the observed species specif-
icity.
These studies used a single static structural model (PDB
#3HHR) to interpret their results. Recently Atwell et al.
[14] showed that mutations can cause large changes in the
ligand structure but that further structural changes created
by mutagenesis can restore function despite the persistence
of widespread structural changes. These data illustrate the
plastic nature of human GH^receptor interaction. These stud-
ies illustrated the functional relationship of distant structural
features with those within the energetically important epitopes
[15] of the site 1 binding interface. The structural plasticity of
this interface was demonstrated when Trp104 of the human
GH receptor, a critical binding residue, was replaced by
Ala. The plasticity of this interface was demonstrated by the
altered spatial relationships between both residues at the bind-
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GH.
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ing interface and additional motifs within the ligand. This
mutation (W104A-human GHbp) created a large cavity in
the site 1 interface and decreased the a⁄nity for wild-type
human GH (Kds 1000 nM). Mutation of human GH residues
which surround Trp104 of the receptor were prepared by a
phage display technique and screened for binding. This ap-
proach identi¢ed a penta-mutant of human GH (K168R,
D171T, K172Y, E174A and F176Y) with a restored a⁄nity
(Kd = 14 nM). The three-dimensional structure of the W104A-
human GHbp in a 1:1 complex with the penta-mutant human
GH was resolved by X-ray crystallography (PDB #1AXI).
This structure revealed local structural changes within ener-
getically crucial epitope of the site 1 binding interface and
substantial changes extending over the entire site 1 contact
interface. Movements of up to 3 Aî were detected for inter-
molecular contact residues that were up to 15 Aî from the
epicenter of this cluster of mutations. For example, a 3 Aî
salt bridge between Lys41 of human GH and Glu127 of the
human GH receptor, located 11 Aî from the mutational epi-
center, was separated by an additional 2.4 Aî in the mutant
complex. This cavity was occupied by two ordered water mol-
ecules. These data suggested that residues 170 in non-primate
and 171 in primate GHs, in addition to interacting with either
Arg43 or Leu43 of primate or non-primate GH receptors, re-
spectively, may also communicate with distant structural fea-
tures that in£uence binding and activation of GH receptors.
The relationship of structural features which lie outside the
functional determinants of site 1 to the structural plasticity
and functional activities of the ligand has not been examined.
To examine the importance of His in the Arg43/Glu171 motif,
the D171H human GH and a H170D bovine GH mutants
were constructed. A static model of human GH would predict
that replacement of Asp171 by His171 should mimic non-pri-
mate GHs and not bind the human GH receptor with high
a⁄nity, while replacement of His170 by Asp170 in bovine GH
should allow for high a⁄nity binding to the human GH re-
ceptor. Failure of this model would suggest that the structural
plasticity of GHs may be a¡ected by distant motifs which may
in£uence species speci¢city.
Sequence alignment of GHs from various species showed
that F44 is only present in primate GHs and thus may o¡er
an additional determinant of species speci¢city. Deletion of
Phe44 from human GH severely reduced its lactogenic activity,
but produced little e¡ect on somatotrophic activity [16]. Phe44
rests within the amino acids missing (residues 32^46) in the
20-kDa variant of human GH [17,18]. 20-kDa human GH
retains a high a⁄nity for the somatotrophic receptor. The
biological activity of 20-kDa human GH has not been re-
ported. Phe44 and the 15 amino acids deleted in the 20-kDa
human GH are distant from Asp171. The smallest distance
between amino acids 32^46 and Asp171 of human GH is 11
Aî ; yet, Atwell’s penta-mutation within the site 1 binding in-
terface induces structural changes within amino acids 32^46
[14]. To investigate the possibility of an interaction between
these distant motifs in human GH, double mutants containing
the D171H mutation and the deletion of either amino acids
32^46 (v32^46/D171H) or Phe44 (vPhe44/D171H) were con-
structed. Finally, bovine GH with Phe inserted between Ser43
and Ile44 (X44F) was constructed with or without the H170D
mutation to determine the contributions of these two motifs in
binding and activation of the human somatotrophic receptor
within the structural context of the bovine protein.
2. Materials and methods
2.1. Plasmids and bacterial strains
An f1 origin of replication was inserted at a unique ClaI site in pT7-
7 plasmid (kindly provided by S. Tabor, Harvard Medial School,
Boston, MA). The negative strand pT7-7 phagemid was used for
cloning, production of single stranded (ss) DNA and expression of
human GH. Escherichia coli strains DH5K, RZ1032 (dut3 and ung3)
and BL21(DE3) were used for cloning, uridine substituted ssDNA
production and protein expression, respectively. A bovine GH expres-
sion system (#53024) was purchased from the American Type Culture
Collection (ATCC). W3110 strain E. coli (ATCC #39936) was pur-
chased for the expression of recombinant bovine GHs.
2.2. Recombinant phagemids and plasmids
The pT7-7 f(3) phagemid for the expression of wild-type human
GH was previously described [16,19]. The pMON3209 bovine GH
expression plasmid was puri¢ed from the purchased expression sys-
tem. Restriction site information for the pMON3209 plasmid was
kindly provided by Dr. G. Bogosian (Monsanto Corporation, Ches-
ter¢eld, MO).
2.3. Site-directed mutagenesis
In vitro mutagenesis was performed by the Kunkel method [16,20].
Selection for positive mutants was facilitated by manipulation of re-
striction endonuclease sites through a primer-introduced translation-
ally silent mutation. Complete DNA sequences in positive clones con-
¢rmed the presence of the desired mutation(s).
To construct mutants of bovine GH, the sequence encoding mature
bovine GH was excised from pMON3209 using EcoRI and BamHI
and ligated into a similarly digested pT7-7f(3) phagemid. Mutagene-
sis was then performed as described above. Coding sequences contain-
ing the desired bovine GH mutations were inserted into the
pMON3209 expression plasmid using these same restriction sites
and sequenced to con¢rm the desired mutations.
2.4. Expression, folding and puri¢cation of human and bovine GHs
Puri¢ed phagemids containing wild-type, vPhe44, 20-kDa, D171H,
vPhe44/D171H or 20-kDa/D171H human GH DNAs were trans-
formed into BL21(DE3) cells and expressed as previously described
[16,19].
Puri¢ed pMON3209 plasmids containing wild-type, H171D, X44F
or H171D/X44F bovine GH were transformed into W3110 E. coli.
One liter cultures of Vogel^Bonner medium [21] containing 100 Wg/ml
of ampicillin and 12.5 Wg/ml of tetracycline were grown to an OD600
of 0.2^0.3 and protein expression induced for 4^6 h with 25 Wg/ml
3L-indoleacrylic acid.
Human and bovine GHs were extracted, refolded and puri¢ed as
previously described for human GH [16,19]. In short, E. coli were
ruptured by a French pressure cell and the inclusion bodies collected
by centrifugation. The inclusion bodies were dissolved in 4.5 M urea
bu¡ered by 100 mM Tris (not pHed). Following dissolution of the
inclusion bodies and removal of bacterial debris, the pH was raised to
between 11.0 and 11.5 to allow the rearrangement of disul¢de bonds.
The preparation was placed into dialysis against 20 mM Tris pH 9.0
to reduce the urea and bring the pH to that desired for puri¢cation,
folding occurred during this process. GHs were puri¢ed by DEAE-
cellulose (DE-52 Whatman, Clifton, NJ), dialyzed against 10 mM
NH4HCO3, and lyophilized.
2.5. Characterization of recombinant proteins
Proteins were evaluated for size and purity by 12% SDS^PAGE
under non-reducing and reducing condition [22]. Absorption and £uo-
rescence spectra were collected to evaluate the folding of each protein
at 20‡C in 10 mM Tris pH 8.2, 150 mM NaCl.
2.6. FDC-P1 somatotrophic assay
FDC-P1 cells containing the human GH receptor were a gift from
Genentech Inc. (South San Francisco, CA). Cells were maintained in
RPMI 1640 containing 10 WM 2-mercaptoethanol, 1 nM human GH
and 10% fetal calf serum [23]. Washed log phase cells were suspended
in medium devoid of human GH and phenol red and returned to the
incubator for 24 h prior to the assay. Stock concentrations of hor-
mones were determined by the bicinchoninic acid/copper sulfate assay
[24]. Hormones were diluted with phenol red-free medium to the de-
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sired concentrations and added to triplicate wells of 96-well plates.
Each well contained 15 000 FDC-P1 cells in a total volume of 100 Wl.
Plates were incubated at 37‡C in a 5% CO2/95% air atmosphere for
48 h. Proliferation was assessed by a vital dye method (Alamar blue,
Accumed International, West Lake, OH) [16]. The data were used to
calculate an ED50 by a four-parameter ¢t method [25].
2.7. Receptor binding assays
Receptor binding assays were performed with temperatures that
were less than the melting temperatures of plasma membranes; there-
fore receptor binding data primarily re£ected binding at site 1 of the
GH ligands. Human GH was iodinated with iodogen (Pierce Chem-
ical Co., Rockford, IL) and carrier-free [125I]iodine to a speci¢c ac-
tivity of 66 WCi/Wg. Binding reactions contained membranes from
2U106 cells in 700 Wl of RPMI 1640 medium supplemented with
25 mM HEPES at pH 7.4, 0.5% bovine albumin, 5 mM MgCl2,
1 mM ZnSO4, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml aproti-
nin, approximately 1 ng of [125I]human GH and various concentra-
tions of human or bovine GHs. Incubations were run for 20 h at
room temperature. Membranes were collected by centrifugation and
membrane-associated [125I]human GH measured. Relative a⁄nities
were calculated by the method of Scatchard [26].
3. Results
3.1. Characterization of recombinant proteins
DNA sequencing con¢rmed the presence of wild-type hu-
man [27] and bovine GHs [28] and the desired mutations.
Final yields for human and bovine GHs were typically be-
tween 10 and 40 mg/l of fermentation. Recombinant human
or bovine GHs co-migrated with National Hormone and Pi-
tuitary Program (NHPP) human or bovine GHs, respectively,
on a 15% SDS polyacrylamide gel under reducing conditions;
co-migration of mutants containing the v32^46 mutation with
the 20.1-kDa molecular weight marker is consistent with the
calculated molecular weight of 20.3 kDa (Fig. 1B). All re-
combinant proteins were homogeneous. Co-migration of re-
combinant proteins with the appropriate NHPP standards on
a non-reducing 15% SDS polyacrylamide gel suggested that all
proteins folded to produce correct disul¢de bonds (Fig. 1A)
[19]. Human GHs containing the v32^46 mutation migrated
faster than the NHPP human GH under non-reducing con-
ditions and appeared to be folded as a single product. Several
human GHs formed small amounts of dimeric hormone that
were evident on non-reducing gels (Fig. 1A). Dimeric hor-
mones were not evident for the bovine GH preparations under
non-reducing conditions.
3.2. Spectroscopy of the recombinant proteins
Normalized absorption spectra (Fig. 2A) of the wild-type
and vPhe44 human GHs overlie each other. Deletion of amino
acids 32^46 in human GH produced a blue shift in the max-
imum absorption from 277 to 269 nm and increased the over-
all absorption. All human GHs containing the D171H muta-
tion show a decrease in absorption in the 270^290 maxima
(Fig. 2A). Addition of the D171H mutation to v32^46 human
GH ameliorates the blue shift and returns the maxima to 277
nm as in wild-type human GH. When the spectra are normal-
ized for absorption at 277 nm, D171H and vPhe44/D171H
have decreased absorptions in the 245^270 nm region while
Fig. 1. Non-reducing (A) and reducing (B) SDS gel electrophoresis.
Electrophoresis of NHPP and recombinant human and bovine GHs
was performed on 12% polyacrylamide gels according to the method
of Laemmli [22]. Proteins were in a solution containing 60 mM
Tris^HCl, 10% glycerol, 1% SDS, 0.01% pyronin-Y with or without
1% 2-mercaptoethanol. Each lane contains 5 Wg of protein.
Fig. 2. UV absorption spectra for human (A) and bovine (B) GHs.
Protein concentrations were 20 WM for GHs. All proteins were in a
solution containing 10 mM Tris^HCl, pH 8.2, containing 150 mM
NaCl. Spectra presented are the average of three scans and were ob-
tained at ambient temperature on a Uvicon model 930 spectropho-
tometer. The raw data (insets) were normalized to absorption at
277 nm.
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the absorptions of v32^46 and v32^46/D171H are increased
relative to the absorption of wild-type human GH.
Normalized absorption spectra (Fig. 2B) of wild-type,
X44F and H171D bovine GHs overlie each other. All re-
combinant bovine GHs have absorption maxima at 277 nm.
The shapes and maxima of the £uorescence spectra (excita-
tion 285 nm) (Fig. 3A) are similar for wild-type, vPhe44,
D171H and vPhe44/D171H human GHs. The spectral maxima
of the v32^46 and v32^46/D171H human GHs were red-
shifted by 2 nm but maintained a shape similar to wild-type
human GH. v32^46 human GH appeared to have a reduced
quantum yield.
The shapes of the £uorescence spectra (excitation 285 nm)
(Fig. 3B) are similar for all recombinant bovine GHs. Re-
placement of His170 with Asp blue-shifted the maxima 5 nm
from 336 nm to 331 nm and reduced the quantum yield rel-
ative to wild-type bovine GH (see inset in Fig. 3B). The max-
imum of X44F bovine GH was blue-shifted 2 nm when com-
pared with the wild-type bovine GH.
3.3. Somatotrophic activities of recombinant proteins
Activities of human and bovine GHs were assessed in the
FDC-P1 somatotrophic bioassay (Fig. 4, Table 1). Replace-
ment of Asp171 with histidine in human GH provided an ED50
of 206 pM which was indistinguishable from wild-type human
GH (ED50 = 162 pM) (Fig. 4A). Elimination of Phe44 (vPhe44)
or amino acids 32^46 (v32^46) in human GH increased the
ED50s to 413 and 392 pM, respectively (Fig. 4A). This small
increase in the ED50 for vPhe44 is consistent with our previ-
ously results [16]. The ED50s of the doubly mutated (vPhe44/
D171H and v32^46/D171H) human GHs were increased ap-
proximately 20-fold to 3265 and 2956 pM, respectively, when
compared to wild-type human GH (Fig. 4B, Table 1). These
increased ED50s for the double mutants were unexpected since
each single mutant only minimally a¡ected somatotrophic ac-
tivity; vPhe44 human GH was the least potent single mutant
with an ED50 increased by 2.5-fold relative to wild-type hu-
man GH. Each of the double-mutated human GHs had so-
matotrophic activities only marginally greater than wild-type
bovine GH (2^3-fold). A structural interaction between these
two positions is indicated by the change in activity of the
double mutants being larger than the sum of the e¡ects of
the individual mutants [21].
Replacement of His170 of bovine GH with Asp enhanced
Fig. 3. Fluorescence spectra for human (A) and bovine (B) GHs.
Protein concentrations were 3.3 and 6.7 WM for human and bovine
GHs, respectively. Proteins were in a solution containing 10 mM
Tris^HCl, pH 8.2, containing 150 mM NaCl. Spectra presented are
the average of three scans. The emission spectra were collected with
a Perkin-Elmer LS-50B at ambient temperature with a 285 nm exci-
tation. The raw data (insets) for each protein were normalized
where the maximum relative £uorescence was set equal to 1.0.
Fig. 4. Somatotrophic activity of a series of single (A) and double
(B) mutants of human and bovine GH. Recombinant GHs were
suspended in 50 mM ammonium bicarbonate. Protein concentra-
tions were determined and dilutions in media were added to FDC-
P1 bioassays as described in Section 2. Data are representative of
three separate experiments. The maximum responses of each hor-
mone were normalized to the maximal response of their respective
wild-type GH.
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the somatotrophic activity via the human GH receptor reduc-
ing the ED50 22-fold from 8329 pM to 369 pM (Fig. 4A). The
somatotrophic activity of H171D bovine GH was only 2.3-
fold less than that for wild-type human GH. In our hands the
FDC-P1 somatotrophic assay can reliably distinguish a two-
fold change in ED50. Insertion of Phe between Ser43 and Ile44
of the wild-type bovine GH decreased the ED50 2.8-fold to
2947 pM. The ED50 for X44F bovine GH is indistinguishable
from v32^46/D171H human GH. The X44F/H170D bovine
GH double mutant had an ED50 improved by 37-fold when
compared with wild-type bovine GH to 227 pM. The ED50 of
X44F/H170D bovine GH is indistinguishable from wild-type
human GH.
The double-mutated bovine GH was a potent mimic of
wild-type human GH. When the ED50 of X44F/H170D bo-
vine GH was compared to the ED50s of either the single-mu-
tated or wild-type bovine GHs (Table 1, ratios in parenthe-
ses), the sum of the e¡ects of single mutations (X44F: 13-fold
and H170D: 1.6-fold) in reducing activity was less than the
reduction observed with wild-type bovine GH (36.6-fold). The
greater than additive e¡ects of these two motifs in bovine GH
document their interaction when activating the human GH
receptor.
3.4. Receptor binding of the recombinant proteins
Correlation coe⁄cients for all human GHs by Scatchard
analyses were s 0.82 (Table 1). Wild-type human GH had a
Kd of 0.30 nM which was in close agreement with published
values [29]. Replacement of Asp171 with histidine increased the
Kd ¢ve-fold to 1.6 nM. Elimination of Phe44 or amino acids
32^46 increased the Kds approximately 10-fold to 3.5 and 2.4
nM, respectively. The human GHs with mutations in both
motifs (vPhe44/D171H and v32^46/D171H human GH) less-
ened the binding a⁄nities by greater than 100-fold producing
Kds of 41 and 42 nM, respectively. These values were in-
creased approximately 10^30-fold over the binding a⁄nities
of any single human GH mutation. The Kds and ED50s for
wild-type and mutant human GHs were highly correlated
(r2 = 0.99). Again, this second measure of activity failed to
follow the additive rule [21] and suggested a structural inter-
action between these two motifs of human GH.
Correlation coe⁄cients for the Scatchard analyses of bovine
GHs were s 0.78. The Kds of wild-type and X44F bovine GH
for the human GH receptor were 39 and 18 nM, respectively
(Table 1). These Kds are approximately 100-fold higher than
that of wild-type human GH. In contrast, the Kd of H170D
bovine GH was decreased 28-fold (Kd = 1.4 nM) to a value
less than ¢ve-fold greater than that for wild-type human GH.
The Kds and ED50s for the bovine GHs were highly correlated
(r2 = 0.98).
4. Discussion
If the species speci¢city of the association between GHs and
the human GH receptor is principally determined by the ionic
interaction between Arg43 of the receptor and the ionic char-
acter of the ligand’s residue at position 170 or 171, then plac-
ing an acidic residue at position 170 of bovine prolactin
should provide full activity and placing a positively charged
residue at position 171 of human GH should greatly reduce
the activity. We observed that replacement of His170 with
aspartic acid in bovine GH decreased the ED50 (369 pM) in
the FDC-P1 somatotrophic assay by 23-fold when compared
with wild-type bovine GH (8329 pM) (Table 1). This decrease
in ED50 was paralleled by a 28-fold increase in a⁄nity for the
human GH receptor (Table 1). The ED50 and Kd of H170D
bovine GH were 2.3- and 4.7-fold less, respectively, than the
values for wild-type human GH. These results con¢rmed the
studies of Laird et al. [9], Souza et al. [11] and Behncken et al.
[13] and were consistent with the hypothesis that the speci¢c
interactions between Arg43 of the human GH receptor and
amino acid 170 of the non-primate GH ligands contributed
to the species speci¢city of the primate GH receptors.
In contrast, replacement of Asp171 with His in human GH
(D171H) failed to signi¢cantly increase the ED50 (only 1.3-
fold) while increasing the Kd by 5.0-fold (Table 1). These
results were consistent to the observations of Behncken et
al. [13] and opposite to what would be expected if the simple
ionic model completely explained species speci¢city. Gobius et
al. [12] reported that rabbit GH receptors which have been
humanized by the replacement of the Leu43 with arginine did
not distinguish between primate and non-primate GHs. Our
results and those of Gobius et al. [12] indicate that additional
structural features play a role in the species speci¢city of the
human GH receptor.
The structural changes created by mutation of GHs pro-
Table 1
ED50 and Kd values for human and bovine growth hormones
Hormone ED50 value for biological activity Relative binding a⁄nity
ED50 (pM) Ratiob Kd (nM) Ratio
WT hGH 162 þ 4.7a 1.0 0.30 1.0
vPhe44 hGH 413 þ 12.5 2.5 3.5 12.0
v32^46 hGH 392 þ 12.5 2.4 2.4 8.0
D171H hGH 206 þ 6.3 1.3 1.6 5.0
vPhe44/D171H hGH 3265 þ 106.8 20.1 41.0 135
v32^46/D171H hGH 2956 þ 98.3 18.2 42.0 140
WT bGH 8329 þ 241.5 51.3 (36.6) 39.0 130
X44F bGH 2947 þ 91.8 18.2 (13.0) 18.0 60
H170D bGH 369 þ 10.0 2.3 (1.6) 1.4 4.7
X44F/H170D bGH 227 þ 6.2 1.4 (1.0) ^ ^
Average coe⁄cient of variation for ED50 determinations = 3.0%
Correlation between ED50 and Kd for human GHs: r2 = 0.99
Correlation between ED50 and Kd for bovine GHs: r2 = 0.98
aMean þ S.D.
bRatios without parentheses are relative to WT hGH, ratios in parentheses are relative to X44F/H170D bGH.
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duced parallel changes in somatotrophic activity and binding
to the human GH receptor (r2 = 0.98^0.99). Binding studies
using membrane fragments were performed at room temper-
ature which is typically below the melting point of membrane
lipids. This condition would not allow the lateral di¡usion of
membrane-bound receptors, thus, primarily allowing binding
to be measured at site 1 of the GH. In addition, both residue
171 and the residues comprising minihelix 1 were structural
determinants of site 1 [10,15]. These data indicated that the
species speci¢city of these GHs was regulated by site 1 bind-
ing.
Deletion of Phe44 or amino acids 32^46 of human GH in-
creased the ED50s only 2^3-fold (Table 1), a change of similar
size to that produced in D171H human GH. In contrast, the
ED50s of doubly mutated human GHs (vPhe44/D171H and
v32^46/D171H) were increased approximately 20-fold. This
reduction of activity was greater than the sum obtained
from individual mutations [30]. These data indicated that
these distant motifs have a functional interaction. Amino
acid 171 and amino acids 32^46 are at least 11 Aî apart.
This distance does not allow a direct physical interaction of
these two motifs. Thus, the interaction between these sites
must be mediated by additional intervening residues.
Our results with bovine GH parallel those with human GH.
Bovine GH mutated in these two motifs (X44F/H170D) mim-
icked the activity of human GH (Table 1). Deletion of Phe44
or the presence of a histidine in position 170 reduced the
biological activity 13- or 1.6-fold, respectively. Wild-type bo-
vine GH was 36-fold less active than the doubly mutated
protein. As with human GH, the sum of the individual func-
tional changes was much less than the reduction of activity of
wild-type bovine GH compared to doubly mutated bovine
GH. Despite the two proteins having only 67% homology,
this relationship described a functional interaction of these
motifs in bovine GH when activating the human GH receptor.
The absorption spectra (Fig. 2A) collected for the human
GHs argued for structural perturbations associated with either
the D171H or v32^46 mutations. In contrast, no structural
perturbations were detected when Phe44 was eliminated from
human GH. Replacement of Asp171 by His decreased absorp-
tion in the 245^270 nm region of the absorption spectra (Fig.
2A) for all human GHs containing this mutation. In contrast,
large increases in absorption were observed across the entire
absorption spectrum for v32^46 deletion mutants, possibly
resulting from the hydration of tyrosines 160 and 164 and
rearrangement of the disul¢de bond angle and/or distance
between cysteines 53 and 165 (Fig. 2A). In doubly mutated
human GH, one mutation appeared to o¡set the absorption
e¡ects of the other mutation. A large perturbation of the four-
helix bundle of the human GHs is also argued against by the
small changes observed in the £uorescence spectrum (Fig. 3A)
which largely represent the status of Trp86 contained within
the core of the four-helix bundle.
Mutational studies of enzymes have demonstrated additive
e¡ects when single mutants were combined in a protein [30].
However, the rule of addition breaks down under two con-
ditions. The ¢rst condition occurs when the mutated residues
interact with each other and no longer behave independently.
These interactions can be the result of physical contact or
indirect contact through electrostatic interactions or structural
perturbations. The second condition arises when the muta-
tion(s) alters either the reaction mechanism or the rate-
limiting step. The rule of addition also applies for multiple
mutations in protein^protein interactions, protein^DNA in-
teractions or protein stability.
When compared to wild-type human GH, wild-type bovine
GH had naturally occurring di¡erences in both motifs, i.e. the
absence of Phe at position 44 and the presence of His at
position 170. Thus, vPhe44/D171H human GH would be pre-
dicted to be the best mimic of bovine GH. This doubly mu-
tated human GH has only a three-fold greater activity than
wild-type bovine GH and a 20-fold lower activity than wild-
type human GH. Thus, these two structural di¡erences can
generally account for the di¡erences in activities of human
and bovine GHs.
In this and other work, predictions based on a static struc-
tural model were only partially e¡ective at predicting the re-
sults of mutations. The recent evidence of GH plasticity in
receptor recognition [14] demonstrates that mutations at the
binding interface have far-reaching structural e¡ects and that
mutations distant from the binding interface can have dramat-
ic e¡ects on the function of a protein [31]. In this work we
have demonstrated that distant mutations have cooperative
e¡ects with mutations within the functional somatotrophic
binding interface.
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